MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
In the citing paper
“targeting of MEK alone is frequently hampered by adaptive resistance, which is complex and context-dependent, and can involve activation of various RTKs, including ERBB family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Cited by
Items 201–300 of 615
Inhibition of SHP2 as an approach to block RAS-driven cancers
Chou, Y., & Bivona, T. G. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.002 · Cited by 33
Ning, C., Liang, M., Liu, S., Wang, G., Edwards, H. J., Xia, Y., Polin, L., Dyson, G. E., Taub, J. W., Mohammad, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17869 · Cited by 33
Hensel, N., Baskal, S., Walter, L. M., Brinkmann, H., Gernert, M., & Claus, P. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.09.005 · Cited by 31
The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
Chesnokov, M. S., Khan, I., Park, Y., Ezell, J., Mehta, G., Yousif, A., Hong, L., Buckanovich, R. J., Takahashi, A., & Chefetz, I. (2021) · Cancers · doi:10.3390/cancers13061369 · Cited by 30
“MEK1/2 selectively activates ERK1/2, its inhibition is an efficient way to suppress the activity of the whole cascade [34].”
BackgroundVerginelli, F., Pisacane, A. M., Gambardella, G., D’Ambrosio, A., Candiello, E., Ferrio, M., Panero, M., Casorzo, L., Benvenuti, S., Cascardi, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22643-w · Cited by 30
Li, B., Xiao, Q., Shan, L., & Song, Y. (2022) · Cell Cycle · doi:10.1080/15384101.2021.2021050 · Cited by 29
“MEK1 and MEK2 are dual-specificity kinases that phosphorylate ERK1 and ERK2 to activate ERK1/2 signaling pathway and thence promote inappropriate cell proliferation and survival [37].”
BackgroundTargeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma
Song, C., Wang, L., Xu, Q., Wang, K., Xie, D., Yu, Z. S., Jiang, K., Liao, L., Yates, J. R., Lee, J., et al. (2017) · Scientific Reports · doi:10.1038/srep46244 · Cited by 37
“Because the phospho-activation of multi pathways is taken as one of the most important resistance mechanisms 8–10 , phospho-activation of parallel MAPK pathways might be critical in drug resistance. siRNAi of upregulated proteins indicated that knockdown of BMK1 impairs the proliferation of CIBM…”
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
Dong, M., Liu, X., Evert, K., Utpatel, K., Peters, M., Zhang, S., Xu, Z., Che, L., Cigliano, A., Ribback, S., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0183-4 · Cited by 27
Selumetinib for the Treatment of Metastatic Uveal Melanoma: Past and Future Perspectives
Komatsubara, K. M., Manson, D. K., & Carvajal, R. D. (2016) · Future Oncology · doi:10.2217/fon-2015-0075 · Cited by 30
Kidger, A. M., Munck, J. M., Saini, H. K., Balmanno, K., Minihane, E., Courtin, A., Graham, B. L., O’Reilly, M., Odle, R., & Cook, S. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0505 · Cited by 36
“First, innate resistance to RAFi orMEKi involves the relief of negative feedback, resulting in the restoration of ERK1/2 activity in the presence of drug, validating the use of ERK1/2 inhibitors (ERKi) in combination to target tumors that are refractory to RAFi or MEKi monotherapy (9, 11).”
BackgroundSelf-citationDecroocq, J., Birsen, R., Montersino, C., Chaskar, P., Mano, J., Poulain, L., Friedrich, C., Alary, A., Guermouche, H., Sahal, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01541-0 · Cited by 30
“Moreover, these RAS−activated cells demonstrated an increased sensitivity to the MEK inhibitor trametinib in vitro, and in vivo in NF1 KO cells, indicating that these cell line models became addicted to oncogenic RAS signaling [6].”
BackgroundInfluentialERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?
Cook, S. J., & Lochhead, P. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.839997 · Cited by 34
“The combination of BRAFi andMEKi is approved for melanoma, but acquired resistance to this combination therapy is common (Chapman et al., 2014; Holderfield et al., 2014; Caunt et al., 2015).”
BackgroundSelf-citationKey roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
Kitai, H., & Ebi, H. (2016) · Small GTPases · doi:10.1080/21541248.2016.1210369 · Cited by 30
“However, MEK inhibitor monotherapy demonstrates only modest efficacy in vitro and in vivo due to 2 primary reasons.(4,5) The first reason is inhibition of MEK and suppression of ERK activity relieves negative”
BackgroundDavis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27584-x · Cited by 27
Gannon, H., Kaplan, N. O., Tsherniak, A., Vázquez, F., Weir, B. A., Hahn, W. C., & Meyerson, M. M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0321 · Cited by 29
“We treated lung cancer cell lines with trametinib and assayed the effect on the KRAS signaling pathway.”
BackgroundResultInfluentialPhosphorylation of PKCδ by FER tips the balance from EGFR degradation to recycling
Lonic, A., Gehling, F., Belle, L., Li, X., Schieber, N. L., Nguyen, E. V., Goodall, G. J., Parton, R. G., Daly, R. J., & Khew‐Goodall, Y. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.201902073 · Cited by 28
mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK
Wu, H., He, D. N., Biswas, S., Shafiquzzaman, M., Zhou, X., Charron, J., Wang, Y., Nayak, B. K., Habib, S. L., Liu, H., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3979 · Cited by 30
“To test whether enhanced ERK activation contributes to renal cyst formation caused by Tsc1 deletion, we crossed Villin-Cre and Villin-Cre;Tsc1 mice to Mek1 mice (40, 41).”
MethodEscaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 30
“Thus, the suppression of ERK activity mediated by MEK inhibition relieves this naturally occurring negative feedback, leading to renewed upstream signaling [52,53].”
BackgroundSubcellular drug targeting illuminates local kinase action
Bucko, P. J., Lombard, C. K., Rathbun, L. I., Garcia, I., Bhat, A., Wordeman, L. G., Smith, F. D., Maly, D. J., Hehnly, H., & Scott, J. D. (2019) · eLife · doi:10.7554/elife.52220 · Cited by 27
“These small molecules are also powerful research tools that can be used to discover new aspects of kinase signaling (Caunt et al., 2015).”
BackgroundFlemington, V., Davies, E. J., Robinson, D. M., Sandin, L. C., Delpuech, O., Zhang, P., Hanson, L. L., Farrington, P. M., Bell, S., Falenta, K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0002 · Cited by 24
“The high prevalence of RAS/MAPK pathway dysregulation in cancer coupled with the chemically tractable protein targets in this pathway has led to the discovery of numerous small-molecule inhibitors that target the three key nodes in this pathway, RAF (6), MEK (7), and ERK (8).”
BackgroundSelf-citationASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
Portelinha, A., Thompson, S. K., Smith, R. A., Ferreira, M. D. S., Asgari, Z., Knežević, A., Seshan, V., de Stanchina, E., Gupta, S., Denis, L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100350 · Cited by 37
“In addition, MEK inhibition has been shown to cause PI3K activation, and PI3K inhibition has been demonstrated to cause ERK activation.(2,37,38) These observations provided an opportunity to develop a mechanism-based combination strategy combining ASN007 with PI3K inhibitors, such as copanlisib, which was recently app…”
BackgroundA receptor-mediated landscape of druggable and targeted nanomaterials for gliomas
Filippo, L. D. D., Carvalho, S. G., Duarte, J. L., Luiz, M. T., Dutra, J. A. P., de Paula, G. A., Chorilli, M., & Conde, J. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100671 · Cited by 34
BDNF-TrkB Signaling Pathway in Spinal Cord Injury: Insights and Implications
Shamsnia, H. S., Peyrovinasab, A., Amirlou, D., Sirouskabiri, S., Rostamian, F., Basiri, N., Shalmani, L. M., Hashemi, M., Hushmandi, K., & Abdolghaffari, A. H. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04381-4 · Cited by 30
“Lastly, we can observe ERK1&2 which is phosphorylated by MEK1&2 [54].”
Antagonistic role of GSK3 isoforms in glioma survival
Vashishtha, V., Jinghan, N., & Yadav, A. K. (2018) · Journal of Cancer · doi:10.7150/jca.21248 · Cited by 25
“Many evidences of ERK1/2 activation been reported in glioma, breast cancer, melanoma, head and neck cancer, lung cancer [36].”
BackgroundIdentification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma
Narayan, R. S., Gasol, A., Slangen, P. L. G., Cornelissen, F. M. G., Lagerweij, T., Veldman, H. Y. Y. E., Dik, R., van den Berg, J., Slotman, B. J., Würdinger, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0480 · Cited by 26
“So far, only trametinib has gained FDA approval (35), whereas MEK162 (binimetinib) is in phase III (36, 37).”
BackgroundCheng, C., Chou, K.-F., Wu, C., Su, N.-W., Peng, C., Su, Y.-W., Chang, J., Ho, A., Lin, H., Chen, C. G., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.017 · Cited by 28
Selumetinib-based therapy in uveal melanoma patient-derived xenografts
Decaudin, D., Botty, R. E., Diallo, B., Massonnet, G., Fleury, J., Naguez, A., Raymondie, C., Davies, E. J., Smith, A., Wilson, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24670 · Cited by 25
“The toxicity of combinations, requiring dose modifications, has been observed with MEK inhibitors and other targeted agents [21].”
Self-citationLin, L., Ding, D., Jiang, Y., Li, Y., & Li, S. (2018) · Oncogenesis · doi:10.1038/s41389-018-0078-y · Cited by 25
RetractedWang, W., Park, C., Oh, E., Sung, Y., Lee, J., Park, K.-H., & Kang, H. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00646 · Cited by 25
Lim, C., Kang, X., Mirabella, V. R., Zhang, H., Bu, Q., Araki, Y., Hoang, E. T., Wang, S., Shen, Y., Choi, S., et al. (2017) · Genes & Development · doi:10.1101/gad.294413.116 · Cited by 26
“…– ERK pathway is one of the best-studied signaling pathways because of its involvement in several key cellular processes, including cell proliferation, differentiation, survival and cell motility, and because of its potential in being a drug target (Samatar and Poulikakos 2014; Caunt et al. 2015).”
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
“In addition, it is formally possible that these RTKs may also directly contribute to intrinsic resistance mechanisms to MEK inhibitors [5].”
BackgroundCombination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
Adamia, S., Bhatt, S., Wen, K., Chyra, Z., Fell, G. G., Tai, Y.-T., Pioso, M. S., Abiatari, I., Letai, A., Dorfman, D. M., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01475-z · Cited by 24
“Several MEK- and CDK-inhibitors have been developed and investigated in preclinical and clinical models to target Ras/Cyclin-D pathways in MM, either single agents or in combination with conventional MM therapy [10, 11].”
BackgroundBardwell, A. J., Lagunes, L., Zebarjedi, R., & Bardwell, L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767087 · Cited by 26
“The success of small-molecule inhibitors of RAF and MEK have validated these efforts; however, the emergence of clinical drug resistance remains a major challenge (3, 4).”
BackgroundDennison, L., Ruggieri, A. N., Mohan, A. A., Leatherman, J. M., Cruz, K. A., Woolman, S., Azad, N. S., Lesinski, G. B., Jaffee, E. M., & Yarchoan, M. M. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0147 · Cited by 26
Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
Zhang, S., Zhou, L., & El‐Deiry, W. S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0149 · Cited by 25
“ERK2 signaling is commonly altered or inappropriately activated in cancer cells due to different cellular stresses including high cellular ROS (24,37).”
You, D., Qiao, Q., Ono, K., Wei, M., Tan, W., Wang, C., Liu, Y., Liu, G., & Zheng, M. (2022) · Aging · doi:10.18632/aging.203908 · Cited by 24
“On activation, Raf mediates phosphorylation of MEK1 and MEK2, which in turn phosphorylate ERK1 and ERK2, correspondingly [10, 11].”
BackgroundYe, Y., Huang, Z., Zhang, M., Li, J., Zhang, Y., & Lou, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114183 · Cited by 28
Harrington, K. M., & Clevenger, C. V. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.726190 · Cited by 24
“Taking into account that ERK1/2 are the only described substrates of MEK1 to date (41, 42), these results implicate activation of the ERK1/2 pathway as being necessary for phosphorylation of Thr-165 within the activation segment of NEK3 in vivo.”
BackgroundRecent developments in mitogen activated protein kinase inhibitors as potential anticancer agents
Singh, V. J., Sharma, B., & Chawla, P. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105161 · Cited by 24
Heightman, T. D., Berdini, V., Bevan, L., Buck, I. M., Carr, M. G., Courtin, A., Coyle, J. E., Day, J. E. H., East, C., Fazal, L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00905 · Cited by 23
Jenkins, L. J., Luk, I. Y., Fairlie, W. D., Lee, E. F., Palmieri, M., Schoffer, K. L., Tan, T., Ng, I., Vukelic, N., Tran, S. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0101 · Cited by 25
“The latter approach may provide greater tumor-speci fi c targeting and a better therapeutic window compared with MEK inhibition where on-target toxicities in normal cells may reduce clinical activity (40).”
Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy
Qi, X.-M., Wang, F., Mortensen, M., Wertz, R., & Chen, G. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.007 · Cited by 23
Peh, J., Boudreau, M. W., Smith, H. M., & Hergenrother, P. J. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.008 · Cited by 29
“Due to the critical role of MEK1/2 kinases in regulating the MAPK pathway (Caunt et al., 2015), its sustained inhibition can be advantageous in significantly delaying the onset of acquired resistance.”
InfluentialCombination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer
Jin, J., Guo, Q., Xie, J., Jin, D., & Zhu, Y. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00592-6 · Cited by 25
Usta, D., Sigaud, R., Buhl, J. L., Selt, F., Marquardt, V., Pauck, D., Jansen, J., Pusch, S., Ecker, J., Hielscher, T., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1021 · Cited by 25
“Trametinib, a dual mechanism MEKi (38), was the top hit in both backgrounds (Fig.”
BackgroundPancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib
Kim, J., Lee, T. S., Lee, M. H., Cho, I. R., Ryu, J. K., Kim, Y., Lee, S. H., & Paik, W. H. (2024) · Cancers · doi:10.3390/cancers16051056 · Cited by 24
Kinoshita, E., Kinoshita‐Kikuta, E., Kubota, Y., Takekawa, M., & Koike, T. (2016) · PROTEOMICS · doi:10.1002/pmic.201500494 · Cited by 22
“Most MEK inhibitors are known to be nonATP-competitive allosteric inhibitors, but the mechanism of action of each MEK inhibitor is distinct [41].”
BackgroundCyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors
Thakuri, P. S., Luker, G. D., & Tavana, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.009 · Cited by 24
Zheng, W., Yang, Z., Song, P., Sun, Y., Liu, P., Yue, L., Lv, K., Wang, X., Shen, Y., Si, J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216029 · Cited by 21
Wu, W., Chordia, M. D., Hart, B. P., Kumarasinghe, E. S., Ji, M. K., Bhargava, A., Lawlor, M. W., Shin, J., Sera, F., Homma, S., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.12.014 · Cited by 21
MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
Li, H., Huang, C., Zhang, Z., Feng, Y., Wang, Z., Tang, X., Zhong, K., Hu, Y., Guo, G. F., Zhou, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01527 · Cited by 20
“Abnormal mitogen-activated protein kinase (MAPK) signaling is associated with the occurrence and development of various cancers [30].”
BackgroundDexmedetomidine reduces ventilator-induced lung injury via ERK1/2 pathway activation
Zhu, C., Yu, J., Wang, B.-Q., Nie, Y., Wang, L., & Shan, S. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11612 · Cited by 21
“It can be stimulated by signals downstream of ras and raf, and extracellular stimuli, such as growth factors and cytokines (39).”
BackgroundMutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies
Mayrhofer, J. E., Enzler, F., Feichtner, A., Röck, R., Fleischmann, J., Raffeiner, A., Tschaikner, P., Ogris, E., Huber, R. G., Hartl, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012150117 · Cited by 20
“Nevertheless, we integrated the MEK1 patient mutations K57E, K57N, and P124S (40, 61).”
InfluentialFragment-Based Discovery of Novel Allosteric MEK1 Binders
Fruscia, P. D., Edfeldt, F., Shamovsky, I. L., Collie, G. W., Aagaard, A., Barlind, L., Börjesson, U., Hansson, E. L., Lewis, R. J., Nilsson, M., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00563 · Cited by 21
Fan, Y., Hou, T., Dan, W., Zhu, Y., Liu, B., Wei, Y., Wang, Z., Gao, Y., Zeng, J., & Li, L. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00951-y · Cited by 23
“ERK1/2 has gradually emerged as a potential therapeutic target for breast cancer, colorectal cancer, melanoma, pancreatic cancer, and PCa [38].”
BackgroundTrentin, L., Bresolin, S., Giarin, E., Bardini, M., Serafin, V., Accordi, B., Fais, F., Tenca, C., Lorenzo, P. D., Valsecchi, M. G., et al. (2016) · Scientific Reports · doi:10.1038/srep34449 · Cited by 20
“We choose to indirectly target RAS using PD0325901, a potent inhibitor of MAP2K1/2 kinase 33 currently in phase II clinical trials 34 .”
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Pant, S., Hubbard, J., Martinelli, E., & Bekaii-Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 18
Arosh, J. A., & Banu, S. K. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.12.011 · Cited by 21
“Extracellular signal-regulated kinase (ERK1/2) and phosphatidylinositide 3-kinase (PI3K) and AKT/protein kinase B (PI3K-AKT) are the well-studied pathways which regulate proliferation, survival, and apoptosis of the cells by integrating multiple intracellular signaling modules [11-14].”
BackgroundKurian, N., Cohen, T. S., Öberg, L., Zan, E. D., Skogberg, G., Vollmer, S., Baturcam, E., Svanberg, P., Bonn, B., Smith, P. D., et al. (2019) · International Journal of COPD · doi:10.2147/copd.s211619 · Cited by 21
“The MEK signaling pathway is recognized as being important in cancer, as such, several small molecule inhibitors of MEK have demonstrated clinical ef fi cacy in certain cancers 29 providing an opportunity for potential repurposing of these assets in COPD.”
BackgroundSelf-citationDJ‐1 inhibits autophagy activity of prostate cancer cells by repressing JNK–Bcl2–Beclin1 signaling
Qin, X., Lu, A., Ke, M., Zhu, W., Ye, X., Wang, G., & Weng, G. (2019) · Cell Biology International · doi:10.1002/cbin.11290 · Cited by 25
High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
Tian, Y., Seifermann, M., Bauer, L., Luchena, C., Wiedmann, J. J., Schmidt, S., Geisel, A., Afonin, S., Höpfner, J., Brehm, M., et al. (2024) · Small · doi:10.1002/smll.202307215 · Cited by 26
Garner, K., Voliotis, M., Alobaid, H. M., Perrett, R. M., Pham, T. T., Tsaneva-Atanasova, K. T., & McArdle, C. A. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1096 · Cited by 20
Comprehensive pharmacological profiling of neurofibromatosis cell lines.
Guo, J., Grovola, M. R., Xie, H. J., Coggins, G. E., Duggan, P., Hasan, R. N., Huang, J., Lin, D. W., Song, C. D., Witek, G. M., et al. (2017) · PubMed · Cited by 26
ERK2 MAP kinase regulates SUFU binding by multisite phosphorylation of GLI1
Bardwell, A. J., Wu, B., Sarin, K. Y., Waterman, M. L., Atwood, S. X., & Bardwell, L. (2022) · Life Science Alliance · doi:10.26508/lsa.202101353 · Cited by 20
“…the SUFU-binding motif. suggest new strategies for targeted intervention in cancer, and improve our understanding of signal crossover and network rewiring in tumor cells (Aberger & Ruiz i Altaba, 2014; Samatar & Poulikakos, 2014; Caunt et al, 2015; Pietrobono et al, 2019; Yesilkanal et al, 2021).”
BackgroundHetero-oligomerization of Rho and Ras GTPases Connects GPCR Activation to mTORC2-AKT Signaling
Senoo, H., Wai, M., Matsubayashi, H. T., Sesaki, H., & Iijima, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108427 · Cited by 22
“The chemoattractant is also known to activate the ERK/MAP pathway via RasC, which involves the activation of Erk2 by phosphorylation (Figures 4C and S4) (Caunt et al., 2015; Nichols et al., 2019; Schwebs et al., 2018).”
BackgroundBalmanno, K., Kidger, A. M., Byrne, D. P., Sale, M. J., Nassman, N., Eyers, P. A., & Cook, S. J. (2023) · Biochemical Journal · doi:10.1042/bcj20220598 · Cited by 17
“Small-molecule BRAF and MEK1/2 inhibitors (RAFi and MEKi) are now approved and used in the clinic to treat BRAF-mutant melanoma [11,12] and BRAF-mutant colorectal cancer [13].”
Self-citationDiscovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold
Lu, B., Huang, S. M., Cao, J., Hu, Q., Shen, R., Wan, H., Wang, D., Yuan, J., Zhang, L. J., Zhang, J., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.019 · Cited by 19
Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy
Chelakkot, V. S., Som, J., Yoshioka, E., Rice, C. P. J., Rutihinda, S. G., & Hirasawa, K. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0586-3 · Cited by 21
Khoury, J. D., Tashakori, M., Yang, H. Y., Loghavi, S., Wang, Y., Wang, J., Piya, S., & Borthakur, G. M. (2020) · Cancers · doi:10.3390/cancers12123511 · Cited by 19
“Against a backdrop of limited efficacy from MEK inhibition [14] and a need to suppress pathway activation, particularly in view of current considerations for including FLT3 inhibitors to frontline AML treatment regimens [15], there is a continued need to explore novel and potent pathway inhibitors.”
BackgroundRationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia
Seipel, K., Schmitter, K., Bacher, U., & Pabst, T. (2019) · Cancers · doi:10.3390/cancers11111779 · Cited by 20
“A number of chemical compounds with varying specificity against MEK kinases have been developed and are currently evaluated in preclinical and clinical cancer trials [9].”
BackgroundProtein kinase A and local signaling in cancer
Rosenthal, K. J., Gordan, J. D., & Scott, J. D. (2024) · Biochemical Journal · doi:10.1042/bcj20230352 · Cited by 20
Hsa-miR-143-3p inhibits Wnt-β-catenin and MAPK signaling in human corneal epithelial stem cells
Kalaimani, L., Devarajan, B., Prajna, N. V., Muthukkaruppan, V., Daniels, J. T., & Chidambaranathan, G. P. (2022) · Scientific Reports · doi:10.1038/s41598-022-15263-x · Cited by 20
MEK inhibitors: a promising targeted therapy for cardiovascular disease
Mohammed, K. A. K., Madeddu, P. R., & Avolio, E. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1404253 · Cited by 20
“Following MEKI treatment, melanoma cancer cells developed advantageous mutations of key molecules of the MAPK pathway — like RAS, RAF, and MEK — to achieve pathway hyperactivation (203 – 205).”
BackgroundCao, N., Lu, Y., Liu, J., Cai, F., Xu, H., Chen, J., Zhang, X., Hua, Z.-C., & Zhuang, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01094 · Cited by 19
“Many cancers exhibit deregulated activation of ERK1/2 signaling and an enhanced dependency on ERK1/2 signaling (Caunt et al., 2015).”
BackgroundBack, J., Nguyen, M. N., Li, L., Lee, S., Lee, I., Chen, F., Gillinov, L. A., Chung, Y., Alder, K. D., Kwon, H., et al. (2021) · Bone Research · doi:10.1038/s41413-021-00158-w · Cited by 21
Pires, L. V., Yi, Y., Cheng, J., Pizzolato, L. S., Cordero, E. A. A., Leung, P. C. K., & Brum, I. S. (2019) · Anticancer Research · doi:10.21873/anticanres.13355 · Cited by 18
Liang, J., Sun, W., Song, H., Wang, C., Li, Q., Li, C., Wei, D., Zhao, Y., Li, C., & Zhang, H. (2021) · Epigenomics · doi:10.2217/epi-2021-0218 · Cited by 17
Zhou, M., Boulos, J. C., Klauck, S. M., & Efferth, T. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09813-w · Cited by 19
“More importantly, MEK is the only known activator of ERK up to date, which can inhibit ERK activation and downstream molecules, thereby inhibiting cell proliferation and survival (Caunt et al. 2015).”
BackgroundHu, X., Li, W., Zeng, K., Xu, Z., Li, C., Kang, Z., Li, S., Huang, X., Han, P., Lin, H., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02927-2 · Cited by 20
“Selective MEK1/2 inhibition may inhibit tumor growth in patients with tumors caused by RAS dysregulation; MEK1/2 are therefore potential actionable therapeutic targets for tumors occurring in patients with NF1 [12, 15].”
BackgroundMechanisms of copy number variants in neuropsychiatric disorders: From genes to therapeutics
Forrest, M. P., & Penzes, P. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102750 · Cited by 21
RAF and MEK Inhibitors in Non-Small Cell Lung Cancer
Adamopoulos, C., Papavassiliou, K. A., Poulikakos, P. I., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094633 · Cited by 18
“…and activation of MEK1/2, which can then phosphorylate and activate ERK1/Activated ERK1/2, and can then phosphorylate several downstream targets of the MAPK pathway, such as transcriptions factors, including AP-1, c-MYC, and ELK-1, that control cell survival and proliferation [17–19].”
BackgroundKinCon: Cell‐based recording of full‐length kinase conformations
Enzler, F., Tschaikner, P., Schneider, R., & Stefan, E. (2020) · IUBMB Life · doi:10.1002/iub.2241 · Cited by 15
Arosh, J. A., Lee, J., & Banu, S. K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111446 · Cited by 18
Rožanc, J., Sakellaropoulos, T., Antoranz, A., Guttà, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0210-8 · Cited by 17
ERF deletion rescues RAS deficiency in mouse embryonic stem cells
Mayor‐Ruiz, C., Olbrich, T., Drosten, M., Lecona, E., Vega-Sendino, M., Ortega, S., Domínguez, O., Barbacid, M., Ruiz, S., & Fernández-Capetillo, Ó. (2018) · Genes & Development · doi:10.1101/gad.310086.117 · Cited by 17
LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex
Wang, J., Wang, Z., Lin, W., Han, Q., Yan, H., Yao, W., Dong, R., Jia, D., Dong, K., & Li, K. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.007 · Cited by 19
Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo
Houweling, M., Abdul, U. K., Brahm, C. G., Lagerweij, T., Heukelom, S., Koken, P. W., Honeywell, R. J., Wedekind, L. E., Peters, G. J., Verheul, H. M. W., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04483-3 · Cited by 16
“Similar results have been observed by other researchers (19–21).”
ResultOrthogonal RNA replication enables directed evolution and Darwinian adaptation in mammalian cells
Ma, L., & Lin, Y. (2025) · Nature Chemical Biology · doi:10.1038/s41589-024-01783-2 · Cited by 19
“Structurally, the recovered mutations that affect residues located within diverse functional domains 59,61,62 (Fig.”
Kuracha, M. R., Thomas, P., Loggie, B. W., & Govindarajan, V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179510 · Cited by 17
Sanmartín-Salinas, P., Toledo-Lobo, M. V., Noguerales-Fraguas, F., Fernández-Contreras, M. E., & Guijarro, L. G. (2017) · Journal of Molecular Histology · doi:10.1007/s10735-017-9745-0 · Cited by 16
“Dysregulation of PI3K and ERK pathways has been implicated in neoplasia, since these two pathways control many aspects of growth and survival in a wide variety of tissues (Caunt et al. 2015; Thorpe et al. 2015).”
BackgroundGastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis
Zu, L., Peng, X., Zeng, Z. R., Wang, J., Meng, L., Shen, W., Hu, C.-T., Yang, Y., & Fu, G. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0782-7 · Cited by 16
Error Tolerance of Machine Learning Algorithms across Contemporary Biological Targets
Kaiser, T. M., & Burger, P. B. (2019) · Molecules · doi:10.3390/molecules24112115 · Cited by 20
Durai, P., Ko, Y., Pan, C., & Park, K. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03643-x · Cited by 19
“Mutations in the genes encoding receptor tyrosine kinases or MEKs lead to deregulation of this signaling pathway, which causes cancer [20].”
BackgroundKobelt, D., Pérez-Hernández, D., Fleuter, C., Dahlmann, M., Zincke, F., Smith, J. L., Migotti, R., Popp, O., Burock, S., Walther, W., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01917-z · Cited by 22
“Since the first description of small molecule inhibitors of MEK several compounds was developed for this purpose including the clinically used drugs AZD6244 (ARRY142886, selumetinib) and GSK1120212 (JTP74057, trametinib) [55, 56].”
BackgroundProfiling MAP kinase cysteines for targeted covalent inhibitor design
Liu, R., Verma, N., Henderson, J. A., Zhan, S., & Shen, J. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00277e · Cited by 15
Past and Future Strategies to Inhibit Membrane Localization of the KRAS Oncogene
Haidar, M., & Jacquemin, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413193 · Cited by 21
“In addition, many studies have shown that treatment with MEK inhibitor leads to an enhancement of the PI3K/AKT pathway, which is due to hyperactivation of ERBB3 [91,92].”
BackgroundAlZahrani, W. M., AlGhamdi, S. A., Zughaibi, T. A., & Rehan, M. (2022) · Pharmaceuticals · doi:10.3390/ph15020195 · Cited by 19
ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses
Lannigan, D. A. (2022) · Endocrinology · doi:10.1210/endocr/bqac106 · Cited by 18
Treatment of KRAS-Mutant Non–Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies
Kaufman, J. M., & Stinchcombe, T. E. (2017) · JAMA · doi:10.1001/jama.2017.3436 · Cited by 17
Huang, A. Y., Zhou, Z., Talukdar, M., Miller, M. B., Chhouk, B., Enyenihi, L., Rosen, I., Stronge, E., Zhao, B., Kim, D., et al. (2024) · doi:10.1101/2024.01.03.574078 · Cited by 16
Metadata
- Authors
- Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J.
- Affiliations
- University of Bath (GB)
- Babraham Institute (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Smith, Paul D.
- Cook, Simon J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 577-592
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1848470479
- Cited by
- 606
- References
- 201
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 61 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 47 · 2019: 62 · 2018: 70 · 2017: 66 · 2016: 33 · 2015: 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14867)
- Biotechnology and Biological Sciences Research Council (BBS/E/B/0000C199, BBS/E/B/000C0417, BBS/E/B/0000H248, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MEK1 inhibitor, ERK signaling, Raf/MEK/ERK pathway, BRAF mutation, RAS mutations, Raf-1, drug resistance mechanisms, carcinogenesis, cancer therapy
- MeSH terms
- Humans, Neoplasms, Signal Transduction, MAP Kinase Signaling System, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.